




Instance: composition-en-c4042d3fb4af6b1a99be10ddedae7598
InstanceOf: CompositionUvEpi
Title: "Composition for pyrukynd Package Leaflet"
Description:  "Composition for pyrukynd Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc4042d3fb4af6b1a99be10ddedae7598)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - pyrukynd"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Pyrukynd is and what it is used for </li>
<li>What you need to know before you take Pyrukynd </li>
<li>How to take Pyrukynd </li>
<li>Possible side effects </li>
<li>How to store Pyrukynd </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What pyrukynd is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What pyrukynd is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pyrukynd contains the active substance mitapivat. </p>
<p>Pyrukynd is used to treat adults with an inherited condition called pyruvate kinase deficiency. Patients 
with pyruvate kinase deficiency have changes to an enzyme in their red blood cells called pyruvate 
kinase, which result in it not working properly. This leads to the red blood cells being broken down 
too fast, a process known as haemolytic anaemia. </p>
<p>Pyrukynd helps the pyruvate kinase enzyme to work better. It increases the energy in your red blood 
cells and stops them from being broken down too fast. </p>
<p>Talk to your doctor, pharmacist or nurse if you have any questions about how Pyrukynd works or why 
this medicine has been prescribed for you. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take pyrukynd"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take pyrukynd"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Pyrukynd  </p>
<ul>
<li>if you are allergic to mitapivat or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor, pharmacist or nurse before taking Pyrukynd. </p>
<p>It is important that you do not stop taking this medicine suddenly because this may lead to worsening 
of your anaemia, with sudden breakdown of red blood cells (acute haemolysis). </p>
<ul>
<li>If you want to stop taking Pyrukynd, talk to your doctor first. </li>
<li>Your doctor will tell you how to stop taking this medicine   usually by reducing the dose 
gradually. This is to prevent any side effects caused by sudden breakdown of the red blood 
cells. </li>
</ul>
<p>See section 4 below for more information about these side effects. </p>
<p>Children and adolescents </p>
<p>Do not give this medicine to children and adolescents under 18 years of age. This is because it is not 
known if mitapivat is safe and effective for them. </p>
<p>Other medicines and Pyrukynd </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, including medicines obtained without a prescription. In particular: </p>
<p>Tell your doctor or pharmacist if you take any of the following medicines because they may increase 
the risk of side effects of Pyrukynd (such as not sleeping) or they may stop Pyrukynd from working 
properly: 
* certain medicines for fungal infections - such as itraconazole<br />
* certain medicines for tuberculosis - such as rifampicin 
* certain medicines for stomach ulcers, heartburn or acid reflux - such as famotidine </p>
<p>Tell your doctor or pharmacist if you take any of the following medicines because Pyrukynd may stop 
these medicines from working properly: 
* certain sedatives - such as midazolam 
* certain birth control (contraceptive) medicines containing hormones - such as ethinylestradiol 
* certain chemotherapy medicines for cancer treatment - such as irinotecan, cyclophosphamide, 
paclitaxel 
* certain medicines to help you stop smoking - such as bupropion 
* certain medicines for stomach ulcers, heartburn or acid reflux - such as omeprazole 
* certain medicines for type 2 diabetes - such as repaglinide 
* certain blood thinners - such as warfarin, dabigatran etexilate 
* certain medicines for heart problems - such as digoxin 
* certain medicines to treat epilepsy - such as carbamazepine, phenytoin, valproic acid<br />
* certain medicines used for strong pain relief - such as alfentanil 
* certain medicines used to prevent organ rejection after an organ transplant - such as 
cyclosporine, sirolimus, tacrolimus 
* certain medicines used to treat an abnormal heart rhythm - such as quinidine 
* certain medicines used to treat migraines - such as ergotamine 
* certain medicines used to treat chronic pain - such as fentanyl 
* certain medicines used to control involuntary movements or sounds - such as pimozide 
* certain medicines used to treat or prevent gout flares - such as colchicine </p>
<p>Pregnancy, breast-feeding and fertility </p>
<p>Pregnancy </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>You should avoid becoming pregnant during treatment with Pyrukynd. 
* This is because it may cause harm to your unborn baby. 
* Talk to your doctor straight away if you become pregnant while taking this medicine. </p>
<p>Breast-feeding </p>
<p>If you plan to breast feed, ask your doctor or pharmacist for advice before taking this medicine. This is 
because it is not known whether the medicine passes into human breast milk or what the effects might 
be on the baby. </p>
<p>Fertility </p>
<p>While taking Pyrukynd, there may be an impact on the ability of a woman and a man to conceive. Talk 
to your doctor or pharmacist for advice if you are planning to have a child. </p>
<p>Contraception for women </p>
<p>If you could become pregnant, you must use reliable contraception while taking Pyrukynd. You must 
also do this for at least 1 month after taking your last dose. 
While you are taking Pyrukynd, some birth control medicines containing hormones (such as pills) may 
not work as well as expected, meaning you might be at risk of becoming pregnant. Talk to your 
doctor, pharmacist or nurse about contraception methods that may be right for you while you are using 
this medicine. </p>
<p>Driving and using machines </p>
<p>You may experience difficulty sleeping (insomnia) during treatment with Pyrukynd. If this happens to 
you, be careful when driving or using machines. </p>
<p>Pyrukynd contains lactose and sodium </p>
<p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take pyrukynd"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take pyrukynd"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>How much to take </p>
<p>The recommended starting dose of Pyrukynd is one 5 mg tablet taken twice a day. Your doctor may 
gradually increase the dose every few weeks based on the results of your blood tests (haemoglobin 
levels) and how well your condition responds, up to a maximum of one 50 mg tablet taken twice a 
day. 
You should keep taking the medicine unless your doctor tells you to stop. </p>
<p>How to take </p>
<p>Pyrukynd is taken by mouth.<br />
* Swallow the tablet whole. 
* You can take it with or without food. 
* Do not split, crush, chew or dissolve the tablets. </p>
<p>Elderly </p>
<p>Pyrukynd has been used in a limited number of patients aged 65 years and older. There is no evidence 
to suggest that elderly patients need a different dose compared to younger adults. </p>
<p>Instructions for opening the blisters </p>
<p>The following pictures show how to take the tablet out of the blister. </p>
<p>Find the correct blister pocket indicated by the day of the week and, if applicable, time of the day 
(morning or evening dose, as shown on the blister by sun and moon symbols). At the corresponding 
tab: </p>
<ol>
<li>Use thumb to PUSH. </li>
</ol>
<p>The image above shows the inside of the blister wallet. </p>
<ol>
<li>Turn package over, PEEL the raised tab on the back. </li>
</ol>
<p>The image above shows the back of the blister wallet. </p>
<ol>
<li>Push tablet through the foil. </li>
</ol>
<p>If you take more Pyrukynd than you should </p>
<p>If you have taken more Pyrukynd than you should, talk to a doctor straight away, or contact your 
nearest accident and emergency department. Take the medicine pack with you so that you can show 
the doctor what you have taken. </p>
<p>If you forget to take Pyrukynd </p>
<ul>
<li>If you miss a dose by 4 hours or less, take it as soon as possible. </li>
<li>If you miss a dose by more than 4 hours, do not take a replacement dose. Take your next 
scheduled dose as you normally would. 
Do not take a double dose to make up for a forgotten dose. </li>
</ul>
<p>If you stop taking Pyrukynd </p>
<p>Do not suddenly stop taking this medicine. 
* If you want to stop taking Pyrukynd, talk to your doctor first. 
* Your doctor will tell you how to stop taking this medicine   usually by reducing the dose 
gradually.<br />
This is to prevent any side effects caused by sudden breakdown of the red blood cells. 
See section 4 below for more information about these side effects. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Very common (may affect more than 1 in 10 people): 
* Difficulty sleeping (insomnia) 
* Decreased levels of the hormone oestrone - seen in blood tests in men 
* Nausea </p>
<p>Common (may affect up to 1 in 10 people): 
* Hot flush 
* Increased levels of the hormone testosterone   seen in blood tests in men 
* Decreased levels of the hormone oestradiol   seen in blood tests in men </p>
<p>Side effects that may occur if you suddenly stop taking Pyrukynd </p>
<p>If you stop taking Pyrukynd suddenly, symptoms may include: 
* being very tired 
* your skin and whites of the eyes going yellow (jaundice) 
* back pain 
* dark urine. 
Talk to your doctor straight away if you have any of these symptoms after stopping this medicine. </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store pyrukynd"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store pyrukynd"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton, blister wallet and blister 
after EXP. The expiry date refers to the last day of that month. </p>
<p>Store below 25 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Pyrukynd contains </p>
<p>The active substance is mitapivat. </p>
<p>Pyrukynd 5 mg film-coated tablets </p>
<p>Each film-coated tablet contains 5 mg of mitapivat (as sulfate). </p>
<p>Pyrukynd 20 mg film-coated tablets </p>
<p>Each film-coated tablet contains 20 mg of mitapivat (as sulfate). </p>
<p>Pyrukynd 50 mg film-coated tablets </p>
<p>Each film-coated tablet contains 50 mg of mitapivat (as sulfate). </p>
<p>Pyrukynd 5 mg, 20 mg and 50 mg film-coated tablets </p>
<p>The other ingredients are:</p>
<ul>
<li>Tablet core: microcrystalline cellulose, croscarmellose sodium, mannitol (E421) and sodium stearyl 
fumarate. </li>
<li>Film-coating: hypromellose (E464), titanium dioxide (E171), lactose monohydrate, triacetin, indigo 
carmine aluminium lake (E132). </li>
<li>Printing ink: shellac (E904), black iron oxide (E172) and ammonium hydroxide (E527). 
See section 2  Pyrukynd contains lactose and sodium . </li>
</ul>
<p>What Pyrukynd looks like and contents of the pack </p>
<p>Pyrukynd 5 mg film-coated tablets are round, blue, film-coated tablets of approximately 5 mm in 
diameter with  M5  printed in black ink on one side and plain on the reverse. </p>
<p>Pyrukynd 20 mg film-coated tablets are round, blue, film-coated tablets of approximately 8 mm in 
diameter with  M20  printed in black ink on one side and plain on the reverse. </p>
<p>Pyrukynd 50 mg film-coated tablets are oblong shaped, blue, film-coated tablets of approximately 
16 mm x 6.8 mm size with  M50  printed in black ink on one side and plain on the reverse. </p>
<p>Packs for starting and continuing treatment </p>
<p>Pyrukynd 5 mg, 20 mg and 50 mg film-coated tablets are available in 4 blister wallets, each containing 
14 film-coated tablets. Each carton contains 56 film-coated tablets. </p>
<p>Packs for reducing or discontinuing treatment </p>
<p>Pyrukynd 5 mg film-coated tablets are also available in blister wallets containing 7 film-coated tablets. </p>
<p>Pyrukynd 20 mg film-coated tablets + Pyrukynd 5 mg film-coated tablets are available in blister 
wallets containing 14 film-coated tablets (7 film-coated tablets of 20 mg + 7 film-coated tablets of 
5 mg). </p>
<p>Pyrukynd 50 mg film-coated tablets + Pyrukynd 20 mg film-coated tablets are available in blister 
wallets containing 14 film-coated tablets (7 film-coated tablets of 50 mg + 7 film-coated tablets of 
20 mg). </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>Agios Netherlands B.V. 
Zuidplein Regus Amsterdam WTC 
1077XV Amsterdam 
The Netherlands </p>
<p>Manufacturer </p>
<p>Almac Pharma Services Limited 
Seagoe Industrial Estate 
Portadown 
Craigavon, County Armagh 
BT63 5UA 
United Kingdom (Northern Ireland) </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments. </p>         </div>"""      



Instance: composition-da-c4042d3fb4af6b1a99be10ddedae7598
InstanceOf: CompositionUvEpi
Title: "Composition for pyrukynd Package Leaflet"
Description:  "Composition for pyrukynd Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc4042d3fb4af6b1a99be10ddedae7598)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - pyrukynd"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Pyrukynd </li>
<li>Sådan skal du tage Pyrukynd </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What pyrukynd is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What pyrukynd is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pyrukynd indeholder det aktive stof mitapivat. </p>
<p>Pyrukynd anvendes til at behandle voksne med en arvelig tilstand, der kaldes pyruvatkinase-mangel. 
Patienter med pyruvatkinase-mangel har ændringer i et enzym i de røde blodlegemer, som kaldes 
pyruvatkinase. Dette medfører, at enzymet ikke virker korrekt, og fører til, at de røde blodlegemer 
bliver nedbrudt for hurtigt, en proces, der kaldes hæmolytisk anæmi. </p>
<p>Pyrukynd hjælper pyruvatkinase-enzymet med at virke bedre. Det øger energien i dine røde 
blodlegemer og forhindrer dem i at blive nedbrudt for hurtigt. </p>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis du har spørgsmål om, hvordan Pyrukynd 
virker, eller hvorfor du har fået ordineret dette lægemiddel. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take pyrukynd"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take pyrukynd"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Pyrukynd </p>
<ul>
<li>hvis du er allergisk over for mitapivat eller et af de øvrige indholdsstoffer i Pyrukynd (angivet i 
punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Pyrukynd. </p>
<p>Det er vigtigt, at du ikke pludselig holder op med at tage dette lægemiddel, da det kan føre til en 
forværring af din anæmi med pludselig nedbrydning af de røde blodlegemer (akut hæmolyse). </p>
<ul>
<li>
<p>Hvis du gerne vil holde op med at tage Pyrukynd, skal du først kontakte lægen. </p>
</li>
<li>
<p>Din læge vil fortælle dig, hvordan du holder op med at tage dette lægemiddel - normalt ved 
gradvist at nedsætte dosen. Dette er for at forhindre bivirkninger forårsaget af en pludselig 
nedbrydning af de røde blodlegemer. </p>
</li>
</ul>
<p>Se punkt 4 nedenunder for flere oplysninger om disse bivirkninger. </p>
<p>Børn og unge </p>
<p>Giv ikke dette lægemiddel til børn og unge under 18 år. Dette skyldes, at det er ukendt, om mitapivat 
er sikkert og effektivt for dem. </p>
<p>Brug af anden medicin sammen med Pyrukynd </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som ikke er købt på 
recept. Du skal især: </p>
<p>Altid fortælle det til lægen eller apotekspersonalet, hvis du tager nogen af de følgende lægemidler, da 
de kan øge risikoen for bivirkninger af Pyrukynd (såsom ikke at kunne sove), eller de kan forhindre, at 
Pyrukynd virker korrekt: </p>
<ul>
<li>
<p>visse lægemidler mod svampeinfektioner - såsom itraconazol </p>
</li>
<li>
<p>visse lægemidler mod tuberkulose - såsom rifampicin </p>
</li>
<li>
<p>visse lægemidler mod mavesår, halsbrand eller sure opstød - såsom famotidin </p>
</li>
</ul>
<p>Altid fortælle det til lægen eller apotekspersonalet, hvis du tager nogen af de følgende lægemidler, da 
Pyrukynd kan forhindre, at disse lægemidler virker korrekt: </p>
<ul>
<li>
<p>visse beroligende lægemidler - såsom midazolam </p>
</li>
<li>
<p>visse former for svangerskabsforebyggende midler (prævention), der indeholder hormoner - såsom ethinyløstradiol </p>
</li>
<li>
<p>visse former for kemoterapi til kræftbehandling - såsom irinotecan, cyklofosfamid, paclitaxel </p>
</li>
<li>
<p>visse lægemidler, der er en hjælp til at holde op med at ryge - såsom bupropion </p>
</li>
<li>
<p>visse lægemidler mod mavesår, halsbrand eller sure opstød - såsom omeprazol </p>
</li>
<li>
<p>visse lægemidler mod type 2-diabetes - såsom repaglinid </p>
</li>
<li>
<p>visse blodfortyndende midler - såsom warfarin eller dabigatranetexilat  </p>
</li>
<li>
<p>visse lægemidler mod hjerteproblemer - såsom digoxin </p>
</li>
<li>
<p>visse lægemidler til behandling af epilepsi - såsom carbamazepin, phenytoin, valproinsyre  </p>
</li>
<li>
<p>visse lægemidler, der bruges til kraftig smertelindring - såsom alfentanil </p>
</li>
<li>
<p>visse lægemidler, der bruges til at forebygge organafstødning efter en organtransplantation - 
såsom ciclosporin, sirolimus, tacrolimus </p>
</li>
<li>
<p>visse lægemidler, der bruges til at behandle en unormal hjerterytme - såsom quinidin </p>
</li>
<li>
<p>visse lægemidler, der bruges til at behandle migræner - såsom ergotamin </p>
</li>
<li>
<p>visse lægemidler, der bruges til at behandle kroniske smerter - såsom fentanyl </p>
</li>
<li>
<p>visse lægemidler, der bruges til at kontrollere ufrivillige bevægelser eller lyde - såsom pimozid </p>
</li>
<li>
<p>visse lægemidler, der bruges til at behandle eller forebygge udbrud af podagra - såsom 
colchicin </p>
</li>
</ul>
<p>Graviditet, amning og frugtbarhed </p>
<p>Graviditet </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Du bør undgå at blive gravid under behandling med Pyrukynd. </p>
<ul>
<li>
<p>Dette skyldes, at det kan skade dit ufødte barn. </p>
</li>
<li>
<p>Kontakt straks lægen, hvis du bliver gravid, mens du tager dette lægemiddel. </p>
</li>
</ul>
<p>Amning </p>
<p>Hvis du planlægger at amme, skal du spørge din læge eller apotekspersonalet til råds, før du tager 
dette lægemiddel. Dette skyldes, at det er ukendt, om lægemidlet udskilles i modermælk, eller hvad 
virkningen kan være på barnet. </p>
<p>Fertilitet </p>
<p>Der kan muligvis være en påvirkning af evnen til at undfange et barn for både kvinder og mænd, mens 
de tager Pyrukynd. Kontakt lægen eller apotekspersonalet for at få rådgivning, hvis du planlægger at 
få et barn. </p>
<p>Prævention til kvinder </p>
<p>Hvis du kan blive gravid, skal du bruge sikker prævention, mens du tager Pyrukynd og i mindst 
1 måned, efter du har taget din sidste dosis. 
Mens du tager Pyrukynd, kan det være, at nogle graviditetsforebyggende lægemidler, der indeholder 
hormoner (såsom p-piller), ikke virker så godt som forventet, hvilket betyder, at du kan have risiko for 
at blive gravid. Kontakt lægen, apotekspersonalet eller sygeplejersken om præventionsmetoder, der 
kan være de rette for dig, mens du bruger dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Du kan have problemer med at sove (insomni) under behandlingen med Pyrukynd. Hvis du oplever 
dette, skal du være forsigtig, hvis du fører motorkøretøj eller betjener maskiner. </p>
<p>Pyrukynd indeholder lactose og natrium </p>
<p>Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take pyrukynd"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take pyrukynd"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Så meget skal der tages </p>
<p>Den anbefalede startdosis af Pyrukynd er én 5 mg tablet, der tages to gange dagligt. Din læge kan 
gradvist øge dosis med et par ugers mellemrum baseret på resultaterne af dine blodprøver 
(hæmoglobinniveauer), og hvor godt din tilstand reagerer, op til maksimalt én 50 mg tablet, der tages 
to gange dagligt. 
Du skal blive ved med at tage lægemidlet, medmindre lægen fortæller dig, at du skal holde op. </p>
<p>Sådan tages lægemidlet </p>
<p>Pyrukynd tages via munden. </p>
<ul>
<li>
<p>Slug tabletten hel. </p>
</li>
<li>
<p>Du kan tage den sammen med eller uden mad. </p>
</li>
<li>
<p>Tabletterne må ikke deles, knuses, tygges eller opløses. </p>
</li>
</ul>
<p>Ældre </p>
<p>Pyrukynd er blevet anvendt hos et begrænset antal patienter i alderen 65 år og ældre. Der er ikke 
noget, der tyder på, at ældre patienter har behov for en anden dosis end yngre voksne. </p>
<p>Anvisninger i at åbne blisteren </p>
<p>De følgende billeder viser, hvordan du skal tage tabletten ud af blisteren. </p>
<p>Find den korrekte blisterlomme, som er mærket med ugedagen og, hvis relevant, tidspunktet på dagen 
(morgen- eller aftendosis som vist på blisteren med sol- og månesymboler). På den relevante flig: </p>
<ol>
<li>TRYK med tommelfingeren. </li>
</ol>
<p>Figuren ovenfor viser indersiden af blistermappen. </p>
<ol>
<li>Vend pakningen, og TRÆK den løftede flig på bagsiden AF. </li>
</ol>
<p>Figuren ovenfor viser bagsiden af blistermappen. </p>
<ol>
<li>Tryk tablet gennem folien. </li>
</ol>
<p>Hvis du har taget for meget Pyrukynd </p>
<p>Hvis du har taget for meget Pyrukynd, skal du straks kontakte lægen eller den nærmeste skadestue. 
Tag lægemiddelpakningen med dig, så du kan vise lægen, hvad du har taget. </p>
<p>Hvis du har glemt at tage Pyrukynd </p>
<ul>
<li>
<p>Hvis der er gået 4 timer eller mindre, siden du skulle have taget din dosis, skal du tage den 
snarest muligt. </p>
</li>
<li>
<p>Hvis der er gået mere end 4 timer, siden du skulle have taget din dosis, må du ikke tage en 
erstatningsdosis. Tag din næste dosis på det planlagte tidspunkt for din næste dosis. 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Hvis du holder op med at tage Pyrukynd </p>
<p>Du må ikke pludselig holde op med at tage dette lægemiddel. </p>
<ul>
<li>
<p>Hvis du gerne vil holde op med at tage Pyrukynd, skal du først kontakte lægen. </p>
</li>
<li>
<p>Din læge vil fortælle dig, hvordan du holder op med at tage dette lægemiddel - normalt ved 
gradvist at nedsætte dosen. 
Dette er for at forhindre bivirkninger forårsaget af en pludselig nedbrydning af de røde blodlegemer. 
Se punkt 4 nedenfor for flere oplysninger om disse bivirkninger. </p>
</li>
</ul>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer): </p>
<ul>
<li>
<p>Søvnbesvær (insomni) </p>
</li>
<li>
<p>Nedsatte niveauer af hormonet østron - kan observeres i blodprøver fra mænd </p>
</li>
<li>
<p>Kvalme </p>
</li>
</ul>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer): </p>
<ul>
<li>
<p>Hedetur </p>
</li>
<li>
<p>Forhøjede niveauer af hormonet testosteron - kan observeres i blodprøver fra mænd </p>
</li>
<li>
<p>Nedsatte niveauer af hormonet østradiol - kan observeres i blodprøver fra mænd </p>
</li>
</ul>
<p>Bivirkninger, der kan forekomme, hvis du pludselig stopper med at tage Pyrukynd </p>
<p>Hvis du pludselig stopper med at tage Pyrukynd, kan symptomerne omfatte: </p>
<ul>
<li>
<p>udpræget træthed </p>
</li>
<li>
<p>din hud og det hvide i øjnene bliver gul (gulsot) </p>
</li>
<li>
<p>rygsmerter </p>
</li>
<li>
<p>mørk urin. </p>
</li>
</ul>
<p>Kontakt straks lægen, hvis du får nogle af disse symptomer, efter du er holdt op med at tage dette 
lægemiddel. </p>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store pyrukynd"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store pyrukynd"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken, blistermappen og blisteren efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares ved temperaturer under 25 °C. 
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pyrukynd indeholder: </p>
<p>Aktivt stof: mitapivat. </p>
<p>Pyrukynd 5 mg filmovertrukne tabletter </p>
<p>Hver filmovertrukket tablet indeholder 5 mg mitapivat (som sulfat). </p>
<p>Pyrukynd 20 mg filmovertrukne tabletter </p>
<p>Hver filmovertrukket tablet indeholder 20 mg mitapivat (som sulfat). </p>
<p>Pyrukynd 50 mg filmovertrukne tabletter </p>
<p>Hver filmovertrukket tablet indeholder 50 mg mitapivat (som sulfat). </p>
<p>Pyrukynd 5 mg, 20 mg og 50 mg filmovertrukne tabletter </p>
<p>Øvrige indholdsstoffer:</p>
<ul>
<li>Tabletkerne: mikrokrystallinsk cellulose, croscarmellosenatrium, mannitol (E421) og 
natriumstearylfumarat. </li>
<li>Filmovertræk: hypromellose (E464), titandioxid (E171), lactosemonohydrat, triacetin, indigo 
carmine aluminium lake (E132). </li>
<li>Prægeblæk: shellac (E904), sort jernoxid (E172) og ammoniumhydroxid (E527). 
Se punkt 2 "Pyrukynd indeholder lactose og natrium". </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Pyrukynd 5 mg filmovertrukne tabletter er runde, blå, filmovertrukne tabletter på ca. 5 mm i diameter 
med "M5" præget med sort blæk på den ene side og uden prægning på den anden side. </p>
<p>Pyrukynd 20 mg filmovertrukne tabletter er runde, blå, filmovertrukne tabletter på ca. 8 mm i diameter 
med "M20" præget med sort blæk på den ene side og uden prægning på den anden side. </p>
<p>Pyrukynd 50 mg filmovertrukne tabletter er aflange, blå, filmovertrukne tabletter på ca. 
16 mm x 6,8 mm med "M50" præget med sort blæk på den ene side og uden prægning på den anden 
side. </p>
<p>Pakning til at starte og fortsætte behandlingen </p>
<p>Pyrukynd 5 mg, 20 mg og 50 mg filmovertrukne tabletter fås i 4 blistermapper, der hver indeholder 
14 filmovertrukne tabletter. Hver æske indeholder 56 filmovertrukne tabletter. </p>
<p>Pakning til at nedsætte eller stoppe behandlingen </p>
<p>Pyrukynd 5 mg filmovertrukne tabletter fås også i blistermapper, der indeholder 7 filmovertrukne 
tabletter. </p>
<p>Pyrukynd 20 mg filmovertrukne tabletter + Pyrukynd 5 mg filmovertrukne tabletter fås i 
blistermapper, der indeholder 14 filmovertrukne tabletter (7 filmovertrukne tabletter af 20 mg + 
7 filmovertrukne tabletter af 5 mg). </p>
<p>Pyrukynd 50 mg filmovertrukne tabletter + Pyrukynd 20 mg filmovertrukne tabletter fås i 
blistermapper, der indeholder 14 filmovertrukne tabletter (7 filmovertrukne tabletter af 50 mg + 
7 filmovertrukne tabletter af 20 mg). </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Agios Netherlands B.V. 
Zuidplein Regus Amsterdam WTC 
1077XV Amsterdam 
Holland </p>
<p>Fremstiller </p>
<p>Almac Pharma Services Limited 
Seagoe Industrial Estate 
Portadown 
Craigavon, County Armagh 
BT63 5UA 
Storbritannien (Nordirland) </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-c4042d3fb4af6b1a99be10ddedae7598
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for pyrukynd Package Leaflet for language en"
Description: "ePI document Bundle for pyrukynd Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-c4042d3fb4af6b1a99be10ddedae7598"
* entry[0].resource = composition-en-c4042d3fb4af6b1a99be10ddedae7598

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpc4042d3fb4af6b1a99be10ddedae7598"
* entry[=].resource = mpc4042d3fb4af6b1a99be10ddedae7598
                            
                    
Instance: bundlepackageleaflet-da-c4042d3fb4af6b1a99be10ddedae7598
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for pyrukynd Package Leaflet for language da"
Description: "ePI document Bundle for pyrukynd Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-c4042d3fb4af6b1a99be10ddedae7598"
* entry[0].resource = composition-da-c4042d3fb4af6b1a99be10ddedae7598

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpc4042d3fb4af6b1a99be10ddedae7598"
* entry[=].resource = mpc4042d3fb4af6b1a99be10ddedae7598
                            
                    



Instance: mpc4042d3fb4af6b1a99be10ddedae7598
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Pyrukynd 5 mg film-coated tablets"
Description: "Pyrukynd 5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1662/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Pyrukynd 5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: c4042d3fb4af6b1a99be10ddedae7598ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "pyrukynd"

* status = #current
* mode = #working

* title = "List of all ePIs associated with pyrukynd"

* subject = Reference(mpc4042d3fb4af6b1a99be10ddedae7598)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#pyrukynd "pyrukynd"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-c4042d3fb4af6b1a99be10ddedae7598) // pyrukynd en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-c4042d3fb4af6b1a99be10ddedae7598) // pyrukynd da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-c4042d3fb4af6b1a99be10ddedae7598
InstanceOf: List

* insert c4042d3fb4af6b1a99be10ddedae7598ListRuleset
    